Engineered Cell and Application Thereof

Abstract

The present invention provides an engineered cell and application thereof. Compared with a wild type cell, the engineered cell lacks or reduces the expression of HLA-A protein and HLA-B protein. The engineered cell disclosed by the present invention can significantly reduce immune rejection response after human hematopoietic cell infusion, and the implantation rate and long-term reconstruction ability in vivo are significantly improved. The cell will significantly expand the use of existing umbilical cord blood and bone marrow donor banks, reduce the need to recruit a large number of donors to match receptors and increase the probability of HLA matching donors, thereby expanding the infusion of clinical-grade allogeneic cells. The engineered cell, as the source of a universal cell, can achieve an HLA matched off-the-shelf cell therapy and has an important clinical transplant transplantation therapy prospect.

CPC Classifications